Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Chantal Pharmaceuticals

This article was originally published in The Rose Sheet

Executive Summary

Chantal Pharmaceuticals: Twelve of 19 "dissident" stockholders have announced an agreement to work with and support the existing Chantal management team, despite an earlier SEC 13D filing, which said they would seek replacements for several top executive and board members including director and CEO Chantal Burnison, Chantal announced July 1. Shareholders have agreed to vote for new executives and board members at the company's annual meeting July 17. Chantal responded to the 13D by filing suit against the stockholders ("The Rose Sheet" June 16, p. 11)...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts